{
    "xml": "<topic id=\"PHP78956\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/monopost\" basename=\"monopost\" title=\"Monopost\">\n<title>Monopost<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP79196\" outputclass=\"patientAndCarerAdvice\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/monopost\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Changes in eye colour</p>\n<p>Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP79206\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/monopost\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (June 2013) that <i>Monopost </i>\n<tm tmtype=\"reg\"/> is accepted for restricted use within NHS Scotland for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who have proven sensitivity to benzalkonium chloride.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP78956",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/monopost",
    "basename": "monopost",
    "title": "Monopost",
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Changes in eye colour",
                "textContent": "Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.",
                "html": "<p>Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (June 2013) that Monopost is accepted for restricted use within NHS Scotland for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who have proven sensitivity to benzalkonium chloride.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (June 2013) that <i>Monopost </i> <tm tmtype=\"reg\"/> is accepted for restricted use within NHS Scotland for the reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who have proven sensitivity to benzalkonium chloride.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}